Chronic Kidney Disease and Antiretroviral Therapy in HIV-Positive Individuals: Recent Developments
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Chronic Kidney Disease and Antiretroviral Therapy in HIV-Positive Individuals : Recent Developments. / Achhra, Amit C; Nugent, Melinda; Mocroft, Amanda; Nielsen, Lene Ryom; Wyatt, Christina M.
I: Current HIV - AIDS Reports, Bind 13, Nr. 3, 2016, s. 149-157.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Chronic Kidney Disease and Antiretroviral Therapy in HIV-Positive Individuals
T2 - Recent Developments
AU - Achhra, Amit C
AU - Nugent, Melinda
AU - Mocroft, Amanda
AU - Nielsen, Lene Ryom
AU - Wyatt, Christina M
PY - 2016
Y1 - 2016
N2 - Chronic kidney disease (CKD) has emerged as an important health concern in HIV-positive individuals. Preventing long-term kidney toxicity from an antiretroviral therapy is therefore critical. Selected antiretroviral agents, especially tenofovir disoproxil fumarate (TDF) and some ritonavir-boosted protease inhibitors (PI/rs), have been associated with increased risk of CKD. However, the CKD risk attributable to these agents is overall small, especially in those with low baseline risk of CKD and normal renal function. CKD risk in HIV-positive individuals can be further minimized by timely identification of those with worsening renal function and discontinuation of potentially nephrotoxic agents. Clinicians can use several monitoring tools, including the D:A:D risk score and routine measurements of estimated glomerular filtration (eGFR) and proteinuria, to identify high-risk individuals who may require an intervention. Tenofovir alafenamide (TAF), a TDF alternative, promises to be safer in terms of TDF-associated kidney and bone toxicity. While the short-term data on TAF does indicate lower eGFR decline and lower risk of proteinuria (vs. TDF), long-term data on renal safety of TAF are still awaited. Promising results have also emerged from recent trials on alternative dual-therapy antiretroviral regimens which exclude the nucleoside(tide) reverse transcriptase class as well as possibly the PI/rs, thereby reducing the drug burden, and possibly the toxicity. However, long-term safety or benefits of these dual-therapy regimens are still unclear and will need to be studied in future prospective studies. Finally, addressing risk factors such as hypertension and diabetes will continue to be important in this population.
AB - Chronic kidney disease (CKD) has emerged as an important health concern in HIV-positive individuals. Preventing long-term kidney toxicity from an antiretroviral therapy is therefore critical. Selected antiretroviral agents, especially tenofovir disoproxil fumarate (TDF) and some ritonavir-boosted protease inhibitors (PI/rs), have been associated with increased risk of CKD. However, the CKD risk attributable to these agents is overall small, especially in those with low baseline risk of CKD and normal renal function. CKD risk in HIV-positive individuals can be further minimized by timely identification of those with worsening renal function and discontinuation of potentially nephrotoxic agents. Clinicians can use several monitoring tools, including the D:A:D risk score and routine measurements of estimated glomerular filtration (eGFR) and proteinuria, to identify high-risk individuals who may require an intervention. Tenofovir alafenamide (TAF), a TDF alternative, promises to be safer in terms of TDF-associated kidney and bone toxicity. While the short-term data on TAF does indicate lower eGFR decline and lower risk of proteinuria (vs. TDF), long-term data on renal safety of TAF are still awaited. Promising results have also emerged from recent trials on alternative dual-therapy antiretroviral regimens which exclude the nucleoside(tide) reverse transcriptase class as well as possibly the PI/rs, thereby reducing the drug burden, and possibly the toxicity. However, long-term safety or benefits of these dual-therapy regimens are still unclear and will need to be studied in future prospective studies. Finally, addressing risk factors such as hypertension and diabetes will continue to be important in this population.
KW - Antiretroviral therapy
KW - cART
KW - Dual therapy
KW - GFR
KW - HAART
KW - HIV
KW - Kidney
KW - Proteinuria
KW - Renal
KW - Tenofovir
U2 - 10.1007/s11904-016-0315-y
DO - 10.1007/s11904-016-0315-y
M3 - Review
C2 - 27130284
AN - SCOPUS:84964596246
VL - 13
SP - 149
EP - 157
JO - Current HIV/AIDS Reports
JF - Current HIV/AIDS Reports
SN - 1548-3568
IS - 3
ER -
ID: 178893159